PCI noninferior to CABG for left main coronary artery disease

November 1, 2016

(HealthDay)—For patients with left main coronary artery disease, percutaneous coronary intervention (PCI) with everolimus-eluting stents is noninferior to coronary artery bypass grafting (CABG), according to a study published online Oct. 31 in the New England Journal of Medicine. The research was published to coincide with the Cardiovascular Research Foundation's Transcatheter Cardiovascular Therapeutics 2016 meeting, held from Oct. 29 to Nov. 2 in Washington, D.C.

Gregg W. Stone, M.D., from New York Presbyterian Hospital in New York City, and colleagues randomized 1,905 patients with left main of low or intermediate anatomical complexity to undergo PCI with fluoropolymer-based cobalt-chromium everolimus-eluting stents (948 patients) or CABG (957 patients).

The researchers found that a primary end point (rate of a composite of death from any cause, stroke, or myocardial infarction at three years) had occurred in 15.4 and 14.7 percent of patients in the PCI and CABG groups, respectively (difference, 0.7 percentage points; P = 0.02 for noninferiority; hazard ratio, 1.00; 95 percent confidence interval, 0.79 to 1.26; P = 0.98 for superiority). The secondary end point event of death, stroke, or myocardial infarction at 30 days occurred in 4.9 and 7.9 percent of patients in the PCI and CABG groups, respectively (P < 0.001 for noninferiority; P = 0.008 for superiority).

"PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or at three years," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Abbott Vascular, which funded the study.

Explore further: Three-year results from the EXCEL trial presented

More information: Abstract
Full Text
Editorial
More Information

Related Stories

Three-year results from the EXCEL trial presented

October 31, 2016
A large-scale randomized trial examining percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) in patients with left main coronary artery disease (LMCAD) and low-intermediate SYNTAX scores ...

Five-year outcomes similar for off-, on-pump CABG in CAD

October 24, 2016
(HealthDay)—Five-year outcomes are similar for patients with coronary artery disease who undergo off-pump or on-pump coronary artery bypass grafting (CABG), according to a study published online Oct. 23 in the New England ...

CABG plus optimal medical therapy best in T2DM and CAD

August 30, 2016
(HealthDay)—For patients with type 2 diabetes and coronary artery disease (CAD), coronary artery bypass grafting (CABG) plus optimal medical therapy (OMT) is superior to percutaneous coronary intervention (PCI) plus OMT, ...

Bioresorbable vascular scaffold deemed noninferior

October 13, 2015
(HealthDay)—For patients with noncomplex obstructive coronary artery disease, treatment with an everolimus-eluting bioresorbable vascular scaffold is noninferior to treatment with an everolimus-eluting cobalt-chromium stent, ...

Stents, bypass surgery equally safe and effective for many with left main heart disease

October 31, 2016
A major international study has found that drug-eluting stents, a less-invasive alternative to bypass surgery, are as effective as surgery for many patients with a blockage in the left main coronary artery.

Rate of CVD mortality, MI, stroke down for patients on semaglutide

September 17, 2016
(HealthDay)—Semaglutide is noninferior to placebo for patients with type 2 diabetes at high cardiovascular risk, according to a study published online Sept. 16 in the New England Journal of Medicine. The research was published ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.